Journal of Behavioral Medicine

, Volume 5, Issue 3, pp 363–373 | Cite as

Informing patients about drug side effects

  • Louis A. Morris
  • David E. Kanouse
Article

Abstract

Two hundred forty-nine newly diagnosed hypertensive patients prescribed thiazide medication were recruited for study. Two-thirds were given a leaflet or patient package insert (PPI) that described the drug and its possible side effects, and one-third were not. At a revisit about 1 month later, patients were asked whether they had experienced any of 17 different “health problems.” For each problem that they experienced, they were asked whether they thought the problem was related to the medicine they were taking. Ten of the health problems were taken verbatim from the PPI's list of possible drug side effects. Patients who received the PPI reported experiencing about the same number of side effects as the non-PPI subjects. However, those who recieved the PPI were more likely to attribute experienced reactions to the drug. This was true both for reactions specifically listed in the PPI and for similar reactions not listed. Results support the notion of an “attribution-labeling” process rather than a “suggestion” effect.

Key words

drug side effects suggestion labeling patient package inserts 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. American Druggist (1978). Editorial. This is the kind of thing FDA has in mind when it talks about requiring PPIs for a wide range of drugs.Am. Drug. 9: 34–35.Google Scholar
  2. Blanc, S., Leuenberger, P., Berger J. P., Brooke, E. M., and Schelling, J. L. (1979). Judgments of trained observers of adverse drug reactions.Clin. Pharmacol. Ther. 25: 493–498.Google Scholar
  3. Blechman, W. J. (1980). Placebo therapy (letter).JAMA 243: 229.Google Scholar
  4. Brown, S. F. (1948). Side reactions to pyribenzamine medication.Proc. Soc. Exp. Biol. Med. 67: 373–374.Google Scholar
  5. Busfield, B. L., Schneller, P., and Capra, D. (1962). Depressive symptom or side effect? A comparative study of symptoms during pre-treatment and treatment periods of patients on three anti-depressant medications.J. Nerv. Ment. Dis. 134: 339–345.Google Scholar
  6. Center for Law and Social Policy (1975). Petition to the Food and Drug Administration to require more adequate labels on prescription drugs, May 31.Google Scholar
  7. Diehl, H. (1933). Medicinal treatment of the common cold.JAMA 101: 2042–2049.Google Scholar
  8. Glaser, E. M., and Whittow, G. C. (1954). Experimental errors in clinical trials.Clin. Sci. 13: 199–210.Google Scholar
  9. Green, D. M. (1964). Pre-existing conditions, placebo reactions and “side effects.”Ann. Intern. Med. 60: 255–265.Google Scholar
  10. Kanouse, D. E., and Morris, L. A. (1978). Patient package inserts: Effects on patient knowledge, attitudes and behavior. Paper presented at 86th Annual American Public Health Association Meeting, Los Angeles.Google Scholar
  11. Loftus, E. F., and Fries, J. F. (1979). Informed consent may be hazardous to health.Science, 204: 11.Google Scholar
  12. Morris, L. A., and Gagliardi, V. J. (1977). The patient package insert as drug education. In Barofsky, I. (ed.),Medication Compliance: A Behavioral Management Approach, C. B. Slack, Thorofare, N. J., pp. 95–104.Google Scholar
  13. Myers, E. D., and Calvert, E. J. (1973). The effect of forewarning on the occurrence of side effects and the discontinuance of medication in patients on amitriptyline.Br. J. Psychiat. 122: 461–464.Google Scholar
  14. Myers, E. D., and Calvert, E. J. (1976). The effect of forewarning on the occurrence of side effects and discontinuance of medication in patients on dothiepin.J. Int. Med. Res. 4: 237–240.Google Scholar
  15. Myers, E. D., and Calvert, E. J. (1978). Knowledge of side effects and the perseverance with medication.Br. J. Psychiat. 132: 526–527.Google Scholar
  16. Paulson, P. T., Bauch, R., Paulson, M. L., and Zilz, D. A. (1976). Medication data sheets-an aid to patient education.Drug. Intel. Clin. Pharmacol. 10: 448–453.Google Scholar
  17. Pogge, R. C. (1963). The toxic placebo. I. Side and toxic effects reported during the administration of placebo medicine.Med. Times 91: 773–778.Google Scholar
  18. Reidenberg, M. M., and Lowenthal, D. T. (1968). Adverse nondrug reactions.N. Engl. J. Med. 279: 678–679.Google Scholar
  19. Shapiro, A. K., Chassan, J., Morris, L. A., and Frick, R. (1974). Placebo-induced side effects.J. Oper. Psychiat. 6: 43–46.Google Scholar
  20. Weibert, R. (1977). Potential distribution problems. Joint symposium on drug information for patients: Patient package inserts.Drug Inform. J. (Suppl.): 11 455–495.Google Scholar

Copyright information

© Plenum Publishing Corporation 1982

Authors and Affiliations

  • Louis A. Morris
    • 1
  • David E. Kanouse
    • 2
  1. 1.HFD-175Food and Drug AdministrationRockville
  2. 2.The Rand CorporationSanta Monica

Personalised recommendations